Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01343550 · ClinicalTrials.gov registry record · Phase 1

Creativity Group for Borderline Personality Disorder

A Phase 1 study of Borderline Personality Disorder, sponsored by State University of New York - Upstate Medical University.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT01343550 is a Phase 1 study of Borderline Personality Disorder that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 20 participants, below the 106-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01343550, a Phase 1 study of Borderline Personality Disorder, has completed, sponsored by State University of New York - Upstate Medical University.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The investigators hypothesize that a creativity skills group for Borderline Personality Disorder can reduce symptoms of BPD, depression, and anxiety.

Interventions

  • OTHER creativity group

Study Locations (1)

New York

  • SUNY Upstate Medical University - Syracuse

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2011-02
Est. Completion 2011-08
Phase Phase 1

What the Registry Record Tells You About NCT01343550

The ClinicalTrials.gov registry entry for NCT01343550 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (81% lower). The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Borderline Personality Disorder appearing as the primary indexed condition, and to 1 intervention - of which creativity group is the first listed.

NCT01343550 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01343550 about?

NCT01343550 is a clinical study titled "Creativity Group for Borderline Personality Disorder". The investigators hypothesize that a creativity skills group for Borderline Personality Disorder can reduce symptoms of BPD, depression, and anxiety.

What is the current status of trial NCT01343550?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-02. Estimated completion is 2011-08.

What conditions does trial NCT01343550 study?

This clinical trial studies the following conditions: Borderline Personality Disorder.

What interventions are being tested in trial NCT01343550?

The interventions under investigation include: creativity group (OTHER).

Who is sponsoring clinical trial NCT01343550?

This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01343550 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Borderline Personality Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.